Generate Biomedicines, Inc.
Financials
Valuation Metrics
Generate Biomedicines, Inc.'s Market Cap is $1.69B. Ranked #2027 of 3,118 in US market (top 65%), #765 of 1,474 on NASDAQ (top 52%), #114 of 157 in Financial Services (top 73%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.69B | US#2,027/3,118 Sec#114/157 |
| Revenue | $31M | US#2,774/3,118 Sec#135/157 |
| Net Income | $-203M | US—/3,118 Sec—/157 |
| Total Assets | $330M | US#2,886/3,118 Sec#155/157 |
| Net Assets | $-616M | US#3,019/3,118 Sec#154/157 |
| Employees | 312 | US#2,400/3,118 Sec#115/157 |
| Value | ||
| P/S | 55.06x | US#2,928/3,118 Sec#155/157 |
| FCF Yield | -12.05% | US—/3,118 Sec—/157 |
| Profitability | ||
| ROA | -61.53% | US#3,012/3,118 Sec#154/157 |
| Op. Margin | -764.26% | US#2,794/3,118 Sec#135/157 |
| Revenue Growth | 67.70% | US#156/3,118 Sec#8/157 |
| Financial Health | ||
| Total Debt | $69M | US#2,529/3,118 Sec#136/157 |
| FCF | $-204M | US#2,779/3,118 Sec#122/157 |
| Cash | $122M | US#2,082/3,118 Sec#121/157 |
| Current Ratio | 2.85x | US#826/3,118 Sec#42/157 |
| Performance | ||
| 1M Return | -3.51% | US#2,103/3,118 Sec#112/157 |
| From 52W High | -41.73% | US#2,208/3,118 Sec#108/157 |
| 1Y MDD | -40.68% | US#1,956/3,118 Sec#103/157 |
| Trading | ||
| Volume | 677,427 shares | US#1,440/3,118 Sec#76/157 |
| Trading Value | $9M | US#2,039/3,118 Sec#109/157 |
| Per Share | ||
| EPS | $-1.58 | US—/3,118 Sec—/157 |
| BPS | $-4.80 | US—/3,118 Sec—/157 |
Company Info
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.